Chronic obstructive pulmonary disease

Sonde Health's Respiratory Responsive Vocal Biomarker Tool Differentiates Patients with Respiratory Conditions from Healthy Individuals

Retrieved on: 
Tuesday, May 23, 2023
Technology, Health, Biometrics, Other Health, Pharmaceutical, Artificial Intelligence, Research, Medical Devices, Software, General Health, Health Technology, Science, Data Management, Medical Supplies, COPD, Deenanath Mangeshkar Hospital, Customer success, Asthma, UC San Diego Health, Albert Einstein College of Medicine, Senior, Journal of Medical Internet Research, COVID-19, Respiratory disease, Agency for Healthcare Research and Quality, Department of Medicine – University of Pamplona, Biomarker, Chronic obstructive pulmonary disease, Hospital, Journal, UC, Patient, Montefiore Medical Center, Data, Machine learning, Risk, AHRQ, JMIR, Pharmaceutical industry, Medical device, Brigham, Medicine

Sonde Health , a health technology company committed to bringing accessible health monitoring to everyone, has revealed new research that demonstrates the ability of its respiratory responsive vocal biomarker (RRVB) machine learning model to differentiate patients with COVID-19 from healthy individuals with about 70% accuracy.

Key Points: 
  • Sonde Health , a health technology company committed to bringing accessible health monitoring to everyone, has revealed new research that demonstrates the ability of its respiratory responsive vocal biomarker (RRVB) machine learning model to differentiate patients with COVID-19 from healthy individuals with about 70% accuracy.
  • The RRVB tool had already shown strong performance in differentiating patients with asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, and cough from healthy individuals.
  • These findings suggest the tool could help uncover respiratory conditions before symptoms arise.
  • The COVID-19 validation study tested this tool for its ability to differentiate patients with COVID-19 from healthy individuals with data collected from September 2020 through April 2021.

Biosency detects early COPD exacerbations thanks to Bora care®, a predictive digital medical device

Retrieved on: 
Thursday, May 25, 2023
COPD, ATS, Respiratory rate, Chronic obstructive pulmonary disease, Death, Vital signs, Patient, Disease, Mortality, WHO, Heart rate, Conference, Pharmaceutical industry, Hospital, OECD

From 2024, Biosency will make its BVS3 technology available to healthcare professionals for integration into the BORA Care® digital medical device, with the aim of obtaining reimbursement as part of an advance payment scheme.

Key Points: 
  • From 2024, Biosency will make its BVS3 technology available to healthcare professionals for integration into the BORA Care® digital medical device, with the aim of obtaining reimbursement as part of an advance payment scheme.
  • It is characterised by chronic respiratory symptoms and exacerbations that can lead to acute respiratory failure and hospitalisation.
  • On 23 May, the company unveiled the first clinical results of the BVS3 early detection algorithm integrated into BORA Care at the ATS conference, demonstrating its ability to predict COPD exacerbations.
  • This opens up the possibilities of using the Bora Care® solution," says Marie Pirotais, President of Biosency.

Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine

Retrieved on: 
Sunday, May 21, 2023
COPD, The New England Journal of Medicine, Depression, Smoking, University, Hospital, Anxiety, ATS, JAMA, Quality of life, Risk, Associate, Cough, NEJM, Sleep, Chronic obstructive pulmonary disease, Periodic breathing, Regeneron Pharmaceuticals, Clinical trial, American Thoracic Society, International Conference on Population and Development, Patient, Health, Death, Conference, News, Disease, Critical Care Medicine (journal), Pharmaceutical industry, Medicine, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, May 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive Phase 3 results evaluating the investigational use of Dupixent® (dupilumab) compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. The Dupixent Phase 3 results were presented in the 2023 American Thoracic Society (ATS) International Conference session “New England Journal of Medicine and JAMA. Discussion on the Edge: Reports of Recently Published Pulmonary Research” and simultaneously published in the New England Journal of Medicine (NEJM). These results will also be presented in the “Breaking News: Clinical Trial Results in Pulmonary Medicine” session on May 22.

Key Points: 
  • The Dupixent Phase 3 results were presented in the 2023 American Thoracic Society (ATS) International Conference session “New England Journal of Medicine and JAMA.
  • Discussion on the Edge: Reports of Recently Published Pulmonary Research” and simultaneously published in the New England Journal of Medicine (NEJM).
  • These results will also be presented in the “Breaking News: Clinical Trial Results in Pulmonary Medicine” session on May 22.
  • The results presented at ATS and published in NEJM are from the BOREAS trial, which met the primary and all key secondary endpoints.

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

Retrieved on: 
Sunday, May 21, 2023
COPD, The New England Journal of Medicine, Depression, Smoking, University, Hospital, Associate professor, Critical Care Medicine (journal), Anxiety, ATS, JAMA, Quality of life, Risk, Cough, NEJM, Sleep, Chronic obstructive pulmonary disease, Periodic breathing, Clinical trial, American Thoracic Society, International Conference on Population and Development, Patient, Health, Death, Conference, News, Disease, Pharmaceutical industry, Dupilumab, Medicine

Discussion on the Edge: Reports of Recently Published Pulmonary Research” and simultaneously published in the New England Journal of Medicine (NEJM).

Key Points: 
  • Discussion on the Edge: Reports of Recently Published Pulmonary Research” and simultaneously published in the New England Journal of Medicine (NEJM).
  • These results will also be presented in the “Breaking News: Clinical Trial Results in Pulmonary Medicine” session on May 22.
  • The results presented at ATS and published in NEJM are from the BOREAS trial, which met the primary and all key secondary endpoints.
  • The safety and efficacy of Dupixent in COPD are currently under clinical investigation and have not been evaluated by any regulatory authority.

Quipt Home Medical Reports Record Second Quarter Fiscal 2023 Financial Results Posting Revenue Growth of 73% and Adjusted EBITDA Growth of 86%

Retrieved on: 
Tuesday, May 16, 2023
COPD, Standby Equity Distribution Agreement, TSX Venture Exchange, Prevalence, CPAP, Toronto Stock Exchange, Registration statement, Calendar, Great Elm, Peer-to-peer file sharing, EDGAR, Sale, Chronic obstructive pulmonary disease, Register, ATM, EBITDA, Acquisition, Patient, Agent, Intermediary, Indian stock exchange, SEDAR, Distribution, TSX, United, Adjustment, Health, Hand, Conference, Tobacco, Cryptocurrency, Health insurance, Security (finance), Bank, Property management, Canaccord Genuity

Revenues for fiscal Q2 2023 were $58.1 million compared to $33.6 million for fiscal Q2 2022, representing a 73% increase year-over-year.

Key Points: 
  • Revenues for fiscal Q2 2023 were $58.1 million compared to $33.6 million for fiscal Q2 2022, representing a 73% increase year-over-year.
  • Recurring Revenue (defined below) for fiscal Q2 2023 continues to be strong and exceeded 78% of revenues.
  • Adjusted EBITDA (defined below) for fiscal Q2 2023 was $13.1 million (22.5% of revenues), compared to Adjusted EBITDA for fiscal Q2 2022 of $7.0 million (21.0% of revenues), representing an 86% increase year-over-year.
  • For fiscal Q2 2023, bad debt expense was at 4.2% of revenues compared to 9.4% in fiscal Q2 2022.

Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD

Retrieved on: 
Thursday, May 11, 2023
GRF, COPD, Infection, MCE, F L S Z Der Kricket DK-1, Inflammation, Chronic obstructive pulmonary disease, Home, Patient, Physician, Risk, Diagnosis, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, News, Food, Dietary supplement, Synthetic oil, Pharmaceutical industry, Grifols

Genetic COPD develops due to a genetic deficiency of alpha1 antitrypsin, a protective plasma protein that safeguards the lungs from inflammation caused by infection and inhaled irritants such as tobacco smoke.

Key Points: 
  • Genetic COPD develops due to a genetic deficiency of alpha1 antitrypsin, a protective plasma protein that safeguards the lungs from inflammation caused by infection and inhaled irritants such as tobacco smoke.
  • Many COPD patients don’t realize their condition could have a genetic component, even though medical guidelines and the COPD Foundation suggest they get screened to learn their genetic risk for alpha-1.
  • This important screening service further strengthens Grifols' firm commitment to the alpha-1 community.”
    “We wholeheartedly support initiatives and innovations that contribute to the diagnosis of alpha-1.
  • Individuals are encouraged to share the results with their doctor, as only a healthcare provider can make a diagnosis of alpha-1.

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
COPD, Maintenance, Abstract, US Foods, D, Conference call, Critical Care Medicine (journal), Pharming, New Drug Application, ATS, Clinical trial, NDA, American Journal of Respiratory and Critical Care Medicine, Quality of life, EDT, Chronic obstructive pulmonary disease, VRNA, Patient, Webcast, Research, FDA, Food, Safety, BST, Pharmaceutical industry, Generic drug, Online shopping, Greater China, Conference

LONDON and RALEIGH, N.C., May 09, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2023, and provides a corporate update.

Key Points: 
  • Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
    LONDON and RALEIGH, N.C., May 09, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2023, and provides a corporate update.
  • An overview of the ENHANCE trial results will be presented as part of the clinical trials symposium reserved for highlighting new breakthroughs.
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Tuesday, May 9, 2023, to discuss the first quarter 2023 financial results and the corporate update.
  • An electronic copy of the first quarter 2023 results press release will also be made available today on the Company’s website.

Global Home Health Market Report 2022: Introduction of AI, Big Data, and Automation Present New Avenues for Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 5, 2023
Managed Care, Health, Well, COPD, Diabetes, CPAP, Hospital, Arthritis, Coronavirus, COVID-19, Cancer, Service, WISH, Element, USD, Government, Chronic obstructive pulmonary disease, Patient, Automation, Nebulizer, Plant growth analysis, Acute respiratory distress syndrome, Diagnosis, AI, Continuous positive airway pressure, Video game, Health insurance, Nursing

The "Global Home Health Market Size, Share, Growth Analysis, By Product, By Service - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Home Health Market Size, Share, Growth Analysis, By Product, By Service - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Old people demand more patient-centric healthcare services, which increases the demand for healthcare workers and agencies, this is expected to drive the market growth.
  • This report provides in-depth analysis of Global Home Health market.
  • The market for home health care will provide more than just health care because of the pandemic.

The Inner Circle Acknowledges, Jahaira L. Serrano, MD, FACCP, as a Pinnacle Life Achiever for her contributions to the medical field

Retrieved on: 
Wednesday, May 3, 2023
COPD, DOS, Asthma, Pneumonia, University, Emphysema, NBPS, Pharynx, Education, University of Puerto Rico School of Dental Medicine, Service, Physician, COVID-19, Chest infection, Diagram, Respiratory system, Multimedia, Mentorship, Mortality, Lung, Pulmonology, Inner circle, Nose, Suite, University of Puerto Rico School of Medicine, Patient, National Board of Medical Examiners, Internal medicine, American College of Chest Physicians, Histology, Chronic obstructive pulmonary disease, American College, Ministry of Health (New Zealand), Medical degree, Nursing, Incidence, Science, MD, Surgeon, Biology, Medicine

ARECIBO, Puerto Rico, May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jahaira L. Serrano, MD, FACCP, is acknowledged as a Pinnacle Life Achiever for her contributions to the medical field.

Key Points: 
  • ARECIBO, Puerto Rico, May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jahaira L. Serrano, MD, FACCP, is acknowledged as a Pinnacle Life Achiever for her contributions to the medical field.
  • Dr. Serrano began her educational pathway at the University of Puerto Rico in Cayey where she earned a Bachelor of Science in Biology.
  • She then attended the University of Puerto Rico School of Medicine in 2002 where she completed a Medical Degree in 2002.
  • According to Dr. Serrano, the NBPS provides continuing board certification for DOs and MDs who uphold medical education and patient care standards.

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

Retrieved on: 
Tuesday, May 2, 2023
COPD, Abstract, Abstract (summary), Conference call, Pharming, ATS, Section, American Journal of Respiratory and Critical Care Medicine, EDT, Chronic obstructive pulmonary disease, VRNA, Clinical trial, MD, Physician, Risk, Webcast, Conference, Critical Care Medicine (journal), BST, Communications satellite, Pharmaceutical industry, News

LONDON and RALEIGH, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces 12 abstracts, including a mini symposium, and a clinical trials symposium, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) have been accepted by the American Thoracic Society International Conference (“ATS”) 2023. An overview of the ENHANCE trial results will be presented as part of the clinical trials symposium ‘Breaking News: Clinical Trial Results in Pulmonary Medicine’ reserved for highlighting new breakthroughs. The abstracts are published on the ATS website and in the publication, American Journal of Respiratory and Critical Care Medicine. Verona Pharma will host a webcast and conference call on Tuesday, May 23, 2023, to review these data.

Key Points: 
  • The abstracts are published on the ATS website and in the publication, American Journal of Respiratory and Critical Care Medicine.
  • Verona Pharma will host a webcast and conference call on Tuesday, May 23, 2023, to review these data.
  • D., Verona Pharma’s President and Chief Executive Officer, said: “We are looking forward to providing additional analyses of the positive results from the Phase 3 ENHANCE trials that highlight key areas of interest for physicians.
  • Details of Verona Pharma’s abstracts and the symposia are listed below and linked to the ATS website.